PubMed · 11004959
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
D Dunn. 2000. Treating glaucoma.. https://doi.org/10.1016/s0001-2092(06)61270-2
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The natural product FR901464 (1) was isolated by the Fujisawa Pharmaceutical Co. and shown to have intriguing biological properties including impressive antitumor activity. In this paper we describe the first total synthesis of 1 in full detail. A chiral building block synthetic strategy was used to assemble the target: optically active components were generated using asymmetric catalytic reactions, and these fragments were coupled together at a late stage in a convergent synthesis. In particular, a versatile, asymmetric hetero-Diels-Alder (HDA) reaction was developed in the context of this synthesis and used with great effectiveness for the preparation of the two densely functionalized pyran rings. The flexible nature of the synthetic route also allowed us to prepare a series of analogues of 1. These compounds were used to prove the relative stereochemistry of the natural product as well as to probe the importance of certain structural features of FR901464 with regard to biological activity.
Dimeric DNA cross-linking compounds have emerged as important new antitumor agents. We report the synthesis and biochemical evaluation of a select set of dimeric mitomycins in which the two mitomycin units are tethered at either the mitomycin C(7) amino or the aziridine N(1a) positions. Significantly, mitomycin C (1) itself is the prototypical bioreductive DNA cross-linking agent. DNA cross-linking experiments using a denaturing-gel-electrophoresis-based assay showed that the extent of DNA cross-linking for select dimeric mitomycins can exceed that of the parent compound, mitomycin C, and that the reaction proceeds, in part, at the two distal C(1) sites in the mitomycins. The efficiency of DNA cross-linking depended on the nature of the linker and the position of linker unit's attachment. When we compared the efficiency of DNA cross-linking for the dimeric mitomycins with their in vitro cytotoxicities in cultured human tumor cells, we observed a poor correlation. The mitomycins that gave the highest levels of DNA cross-linked adducts displayed the weakest cytotoxicities. These findings determined that the denaturing-gel-electrophoresis-based assay was a poor predictor of cytotoxic activity.
Iron complexes of daunorubicin, idarubicin, pirarubicin, and doxorubicin in anhydrous DMF were studied by UV/vis, CD, fluorescence, Mössbauer, and EPR spectroscopy. Titration studies of the metal-free anthracyclines showed one (UV-detectable) deprotonation step requiring 2 equiv of base, compared to 1 equiv for quinizarine. Metal complexation was studied at three different metal/ligand ratios, and with increasing amounts of base. The results obtained from optical spectroscopy show the existence of two different complex species and give clear indications for the requirements of metal complexation. Complex species I, formed at a low iron-to-ligand ratio, is less dependent on base addition than complex species II formed with equimolar ferric ion. EPR and Mössbauer experiments provide further insight into the structures of both complex species. Lack of spin density of the Mössbauer samples in EPR indicates spin coupling between the metal centers. Mössbauer spectra consist of single quadrupole doublets with values typical for high-spin ferric ion in an octahedral arrangement. The Mössbauer spectroscopic features at 7 T exclude the presence of S = 0 dimers. Complex I represents a monomeric ferric iron complex whereas complex II is consistent with a more or less aggregrated oligomeric Fe-anthracycline system.